Literature DB >> 24862326

HIV-1 Tat disrupts CX3CL1-CX3CR1 axis in microglia via the NF-κBYY1 pathway.

Ming Duan, Honghong Yao, Yu Cai, Ke Liao, Pankaj Seth, Shilpa Buch1.   

Abstract

Microglia are critical for the pathogenesis of HIV-associated dementia not only by acting as conduits of viral entry but also as reservoirs for productive and latent virus infection, and as producers of neurotoxins. Interaction between CX3CL1 (fractalkine) and FKN receptor (CX3CR1) is highly functional in the brain, and is known to regulate a complex network of paracrine and autocrine interactions between neurons and microglia. The aim of the present study was to determine which extent of HIV-1 Tat protein causes the alteration of CX3CR1 expression and to investigate the regulatory mechanism for CX3CR1 expression. Here we showed that exposure of primary microglia and BV2 cells to exogenous Tat protein resulted in down-regulation of CX3CR1 mRNA and protein expression, with a concomitant induction of proinflammatory responses. Next, we further showed that NF-κB activation by Tat treatment negatively regulated CX3CR1 expression. Since a YY1 binding site ~10kb upstream of CX3CR1 promoter was predicted in rats, mice and humans, the classical NF-κB-YY1 regulatory pathway was considered. Our findings indicated that Tat repressed CX3CR1 expression via NF-κB-YY1 regulatory pathway. To gain insight into the effect of Tat on CX3CL1-CX3CR1 communication, calcium mobilization, MAPK activation and microglial migration, respectively, were tested in microglial cells after successive treatment with Tat and CX3CL1. The results suggested that Tat disrupted the responses of microglia to CX3CL1. Taken together, these results demonstrate that HIV-1 Tat protein suppresses CX3CR1 expression in microglia via NF-κB-YY1 pathway and attenuates CX3CL1-induced functional response of microglia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24862326      PMCID: PMC5003019          DOI: 10.2174/1570162x12666140526123119

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  53 in total

1.  CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents.

Authors:  Raffaela Cipriani; Pia Villa; Giuseppina Chece; Clotilde Lauro; Alessandra Paladini; Edoardo Micotti; Carlo Perego; Maria-Grazia De Simoni; Bertil B Fredholm; Fabrizio Eusebi; Cristina Limatola
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues.

Authors:  L Hudson; J Liu; A Nath; M Jones; R Raghavan; O Narayan; D Male; I Everall
Journal:  J Neurovirol       Date:  2000-04       Impact factor: 2.643

3.  HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region.

Authors:  H C Chang; F Samaniego; B C Nair; L Buonaguro; B Ensoli
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

4.  Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages.

Authors:  Dustin J Donnelly; Erin E Longbrake; Todd M Shawler; Kristina A Kigerl; Wenmin Lai; C Amy Tovar; Richard M Ransohoff; Phillip G Popovich
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

5.  Functional expression of the fractalkine (CX3C) receptor and its regulation by lipopolysaccharide in rat microglia.

Authors:  E W Boddeke; I Meigel; S Frentzel; K Biber; L Q Renn; P Gebicke-Härter
Journal:  Eur J Pharmacol       Date:  1999-06-18       Impact factor: 4.432

6.  CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes.

Authors:  Franziska Schwartzkopff; Frank Petersen; Tobias Alexander Grimm; Ernst Brandt
Journal:  Innate Immun       Date:  2010-11-18       Impact factor: 2.680

7.  The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.

Authors:  Christian Hundhausen; Dominika Misztela; Theo A Berkhout; Neil Broadway; Paul Saftig; Karina Reiss; Dieter Hartmann; Falk Fahrenholz; Rolf Postina; Vance Matthews; Karl-Josef Kallen; Stefan Rose-John; Andreas Ludwig
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

Review 8.  Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions.

Authors:  Luisa Minghetti; Sergio Visentin; Mario Patrizio; Laura Franchini; Maria Antonietta Ajmone-Cat; Giulio Levi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

9.  RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells.

Authors:  Yurika Saitoh; Keiichi Koizumi; Hiroaki Sakurai; Takayuki Minami; Ikuo Saiki
Journal:  Biochem Biophys Res Commun       Date:  2007-10-22       Impact factor: 3.575

10.  Interleukin-10 and interferon-gamma modulate surface expression of fractalkine-receptor (CX(3)CR1) via PI3K in monocytes.

Authors:  María V Ramos; Gabriela C Fernández; Romina J Fernández Brando; Cecilia A Panek; Leticia V Bentancor; Verónica I Landoni; Martín A Isturiz; Marina S Palermo
Journal:  Immunology       Date:  2009-09-09       Impact factor: 7.397

View more
  11 in total

1.  Mesenchymal Stem Cells Modulate the Functional Properties of Microglia via TGF-β Secretion.

Authors:  Min Young Noh; Su Min Lim; Ki-Wook Oh; Kyung-Ah Cho; Jinseok Park; Kyung-Suk Kim; Su-Jung Lee; Min-Soo Kwon; Seung Hyun Kim
Journal:  Stem Cells Transl Med       Date:  2016-07-08       Impact factor: 6.940

2.  Crocin Upregulates CX3CR1 Expression by Suppressing NF-κB/YY1 Signaling and Inhibiting Lipopolysaccharide-Induced Microglial Activation.

Authors:  Bochang Lv; Fuquan Huo; Zhongqiao Zhu; Zhiguo Xu; Xiaojie Dang; Tao Chen; Ting Zhang; Xinguang Yang
Journal:  Neurochem Res       Date:  2016-04-15       Impact factor: 3.996

Review 3.  Immune activation in the central nervous system throughout the course of HIV infection.

Authors:  Serena S Spudich
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

4.  HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy.

Authors:  Annadurai Thangaraj; Palsamy Periyasamy; Ke Liao; Venkata Sunil Bendi; Shannon Callen; Gurudutt Pendyala; Shilpa Buch
Journal:  Autophagy       Date:  2018-07-26       Impact factor: 16.016

5.  Cocaine-mediated induction of microglial activation involves the ER stress-TLR2 axis.

Authors:  Ke Liao; Minglei Guo; Fang Niu; Lu Yang; Shannon E Callen; Shilpa Buch
Journal:  J Neuroinflammation       Date:  2016-02-09       Impact factor: 8.322

Review 6.  Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications.

Authors:  Guoku Hu; Lu Yang; Yu Cai; Fang Niu; Frank Mezzacappa; Shannon Callen; Howard S Fox; Shilpa Buch
Journal:  Cell Death Dis       Date:  2016-11-24       Impact factor: 8.469

7.  Neurodevelopmental Processes in the Prefrontal Cortex Derailed by Chronic HIV-1 Viral Protein Exposure.

Authors:  Kristen A McLaurin; Hailong Li; Rosemarie M Booze; Charles F Mactutus
Journal:  Cells       Date:  2021-11-05       Impact factor: 6.600

Review 8.  The Function of NF-Kappa B During Epilepsy, a Potential Therapeutic Target.

Authors:  Mengtan Cai; Weihong Lin
Journal:  Front Neurosci       Date:  2022-03-10       Impact factor: 4.677

Review 9.  The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders.

Authors:  Sonia Mediouni; Maria Cecilia Garibaldi Marcondes; Courtney Miller; Jay P McLaughlin; Susana T Valente
Journal:  Front Microbiol       Date:  2015-10-23       Impact factor: 5.640

10.  Neuroinflammatory Profiling in SIV-Infected Chinese-Origin Rhesus Macaques on Antiretroviral Therapy.

Authors:  Antonio Solis-Leal; Summer Siddiqui; Fei Wu; Mahesh Mohan; Wenhui Hu; Lara A Doyle-Meyers; Jason P Dufour; Binhua Ling
Journal:  Viruses       Date:  2022-01-13       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.